MicroCyto Raises Over RMB 300 Million in Series A Financing, CEC Capital Acts as Sole Financial Advisor

MicroCyto announced that it has raised over 300 million yuan in Series A financing. The round was led by Beijing Jingguorui Investment, with participation from Beijing Medical and Health Industry Investment Fund, Shenzhen Capital Group, and Hebei Production Investment Jincai Synthetic Equity Investment Fund. Existing investors Shunxi Venture Capital and Huirong Fund of Henan Investment Group also increased their investments. The funds raised in this round will primarily be used to advance the commercialization of several products and the construction of Microcyto's production base in Beidaihe.

CEC Capital served as the sole financial advisor to MicroCyto in this transaction.

Founded in 2022, MicroCyto is dedicated to technological innovation and industrialization in synthetic biology. The company provides bio-based raw materials and solutions for clients in sectors such as pharmaceuticals, personal care, agriculture, food, feed, and materials through green production methods. Its current key products include sugar alcohols and rare sugars, natural pigments, and active molecules.